Wet Heparinized Suction for Abdominal Cancer

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Sep 7, 2021

Keywords

ClinConnect Summary

This clinical trial is looking to improve the way doctors collect tissue samples from patients with certain types of abdominal cancers, including cancers of the pancreas, stomach, esophagus, and liver. The researchers want to see if using a blood thinner (an anticoagulant) or a saltwater solution during the sampling process helps get better quality tissue samples. Additionally, they will test whether using a special filter, called a microsieve, can help doctors evaluate the samples before they are sent for testing.

To participate in this study, you need to be at least 18 years old and have a solid mass in your abdomen that can be seen on imaging tests like ultrasound or CT scans. You also need to have a certain level of blood platelets and meet other health criteria. If you decide to join, you'll be randomly assigned to receive either the blood thinner or the saltwater during the procedure. The study will include 42 participants at one site in the United States, and it is not yet recruiting participants. This trial aims to enhance the accuracy of tissue diagnoses, which can play a crucial role in your treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 year
• • Non-pregnant Patients
• • Patients with the presence of a solid abdominal mass as seen on diagnostic imaging \[ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)\] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA/FNB for solid pancreatic mass and did not receive a conclusive diagnosis
• • Patients with platelet count \> 50,000
• • Patients with International Normalized Ratio (INR) \< 1.5
• Exclusion Criteria:
• • Age \< 18 years
• • Pregnant Patients
• • Patients who cannot consent for themselves
• • Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days
• • Patients with cystic abdominal masses
• • Patients with a platelet count \< 50,000
• • Patients with an INR \> 1.5
• • Patients with a heparin or porcine allergy
• • Patients with prior heparin induced thrombocytopenia (HIT)
• • Patient's with religious aversion to porcine-containing products